[Construction of a Prognostic Prediction Model of Patients with Pathologic N0  in Resected Invasive Mucinous Adenocarcinoma of the Lung]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2024 Jan 31

PMID 38296625

Authors

Zheng Wang

Jinxian He

Haibo Shen

Xiaohan Chen

Chengbin Lin

Hongyan Yu

Jiajun Gao

Xianneng He

Weiyu Shen

Affiliations

Soon will be listed here.

Abstract

Background: Invasive mucinous adenocarcinoma (IMA) was a rare and specific type of lung adenocarcinoma, which was often characterized by fewer lymphatic metastases. Therefore, it was difficult to evaluate the prognosis of these tumors based on the existing tumor-node-metastasis (TNM) staging. So, this study aimed to develop Nomograms to predict outcomes of patients with pathologic N0 in resected IMA.

Methods: According to the inclusion criteria and exclusion criteria, IMA patients with pathologic N0 in The Affiliated Lihuili Hospital of Ningbo University (training cohort, n=78) and Ningbo No.2 Hospital (validation cohort, n=66) were reviewed between July 2012 and May 2017. The prognostic value of the clinicopathological features in the training cohort was analyzed and prognostic prediction models were established, and the performances of models were evaluated. Finally, the validation cohort data was put in for external validation.

Results: Univariate analysis showed that pneumonic type, larger tumor size, mixed mucinous/non-mucinous component, and higher overall stage were significant influence factors of 5-year progression-free survival (PFS) and overall survival (OS). Multivariate analysis further indicated that type of imaging, tumor size, mucinous component were the independent prognostic factors for poor 5-year PFS and OS. Moreover, the 5-year PFS and OS rates were 62.82% and 75.64%, respectively. In subgroups, the survival analysis also showed that the pneumonic type and mixed mucinous/non-mucinous patients had significantly poorer 5-year PFS and OS compared with solitary type and pure mucinous patients, respectively. The C-index of Nomograms with 5-year PFS and OS were 0.815 (95%CI: 0.741-0.889) and 0.767 (95%CI: 0.669-0.865). The calibration curve and decision curve analysis (DCA) of both models showed good predictive performances in both cohorts.

Conclusions: The Nomograms based on clinicopathological characteristics in a certain extent, can be used as an effective prognostic tool for patients with pathologic N0 after IMA resection.

References

Wang T, Yang Y, Liu X, Deng J, Wu J, Hou L . Primary Invasive Mucinous Adenocarcinoma of the Lung: Prognostic Value of CT Imaging Features Combined with Clinical Factors. Korean J Radiol. 2020; 22(4):652-662. PMC: 8005341. DOI: 10.3348/kjr.2020.0454. View

Bhatia R, Gautam S, Cannon A, Thompson C, Hall B, Aithal A . Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019; 38(1-2):223-236. PMC: 6614013. DOI: 10.1007/s10555-018-09775-0. View

Russell P, Wainer Z, Wright G, Daniels M, Conron M, Williams R . Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung.... J Thorac Oncol. 2011; 6(9):1496-504. DOI: 10.1097/JTO.0b013e318221f701. View

Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M . Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. Onco Targets Ther. 2017; 10:153-163. PMC: 5207454. DOI: 10.2147/OTT.S121059. View

Hwang D, Sholl L, Rojas-Rudilla V, Hall D, Shivdasani P, Garcia E . KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2016; 11(4):496-503. DOI: 10.1016/j.jtho.2016.01.010. View

Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T . Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 2011; 117(18):4257-66. DOI: 10.1002/cncr.26010. View

Watanabe H, Saito H, Yokose T, Sakuma Y, Murakami S, Kondo T . Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. Ann Thorac Surg. 2015; 99(3):975-81. DOI: 10.1016/j.athoracsur.2014.10.065. View

Finberg K, Sequist L, Joshi V, Muzikansky A, Miller J, Han M . Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007; 9(3):320-6. PMC: 1899415. DOI: 10.2353/jmoldx.2007.060182. View

Kadota K, Nitadori J, Sima C, Ujiie H, Rizk N, Jones D . Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol. 2015; 10(5):806-814. PMC: 4500042. DOI: 10.1097/JTO.0000000000000486. View

10.

Geles A, Gruber-Moesenbacher U, Quehenberger F, Manzl C, Al Effah M, Grygar E . Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch. 2015; 467(6):675-686. DOI: 10.1007/s00428-015-1852-2. View

11.

Kish J, Ro J, Ayala A, McMurtrey M . Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol. 1989; 20(11):1097-102. DOI: 10.1016/0046-8177(89)90229-3. View

12.

Travis W, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y . International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6(2):244-85. PMC: 4513953. DOI: 10.1097/JTO.0b013e318206a221. View

13.

Cha Y, Shim H . Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res. 2017; 6(5):508-512. PMC: 5653530. DOI: 10.21037/tlcr.2017.06.10. View

14.

Kim W, Lee S, Lee J, Seo J, Kim H, Kim J . Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?. Korean J Radiol. 2022; 23(3):370-380. PMC: 8876658. DOI: 10.3348/kjr.2021.0465. View

15.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

16.

Shim H, Kenudson M, Zheng Z, Liebers M, Cha Y, Hoang Ho Q . Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2015; 10(8):1156-62. DOI: 10.1097/JTO.0000000000000579. View

17.

Lee H, Cha M, Lee K, Lee H, Kwon O, Choi J . Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas. J Thorac Oncol. 2016; 11(7):1064-73. DOI: 10.1016/j.jtho.2016.03.011. View

18.

Matsui T, Sakakura N, Koyama S, Nakanishi K, Sasaki E, Kato S . Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma. Ann Thorac Surg. 2020; 112(4):1118-1126. DOI: 10.1016/j.athoracsur.2020.09.042. View

19.

Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W . Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. J Cancer Res Clin Oncol. 2016; 142(8):1837-45. DOI: 10.1007/s00432-016-2201-9. View

20.

Zhang G, Wang X, Jia J, Zuo Z, Wang L, Gao S . Development and validation of a nomogram for predicting survival in patients with surgically resected lung invasive mucinous adenocarcinoma. Transl Lung Cancer Res. 2022; 10(12):4445-4458. PMC: 8743532. DOI: 10.21037/tlcr-21-562. View

[Construction of a Prognostic Prediction Model of Patients with Pathologic N0 in Resected Invasive Mucinous Adenocarcinoma of the Lung]

[Construction of a Prognostic Prediction Model of Patients with Pathologic N0  in Resected Invasive Mucinous Adenocarcinoma of the Lung]